Nanexa AB (NANEXA) - Total Assets
Based on the latest financial reports, Nanexa AB (NANEXA) holds total assets worth Skr154.68 Million SEK (≈ $16.65 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Nanexa AB - Total Assets Trend (2014–2025)
This chart illustrates how Nanexa AB's total assets have evolved over time, based on quarterly financial data. Also see market cap of Nanexa AB for the company's overall valuation and market capitalisation.
Nanexa AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Nanexa AB's total assets of Skr154.68 Million consist of 38.8% current assets and 61.2% non-current assets. Review Nanexa AB (NANEXA) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 5.9% |
| Accounts Receivable | Skr5.70 Million | 4.1% |
| Inventory | Skr128.00K | 0.1% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr74.31 Million | 53.8% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Nanexa AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Nanexa AB stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nanexa AB's current assets represent 38.8% of total assets in 2025, an increase from 0.2% in 2014.
- Cash Position: Cash and equivalents constituted 5.9% of total assets in 2025, up from 0.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 53.0% of total assets, a decrease from 99.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 53.8% of total assets.
Nanexa AB Competitors by Total Assets
Key competitors of Nanexa AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥5.73 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
Nanexa AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.89 | 3.11 | 15.79 |
| Quick Ratio | 2.89 | 3.08 | 15.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr39.66 Million | Skr31.86 Million | Skr115.37 Million |
Nanexa AB - Advanced Valuation Insights
This section examines the relationship between Nanexa AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.40 |
| Latest Market Cap to Assets Ratio | 0.85 |
| Asset Growth Rate (YoY) | 50.4% |
| Total Assets | Skr138.14 Million |
| Market Capitalization | $116.93 Million USD |
Valuation Analysis
Near Book Valuation: The market values Nanexa AB's assets close to their book value (0.85x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Nanexa AB's assets grew by 50.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Nanexa AB (2014–2025)
The table below shows the annual total assets of Nanexa AB from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr138.14 Million ≈ $14.87 Million |
+50.45% |
| 2024-12-31 | Skr91.82 Million ≈ $9.88 Million |
-30.57% |
| 2023-12-31 | Skr132.26 Million ≈ $14.23 Million |
-22.29% |
| 2022-12-31 | Skr170.19 Million ≈ $18.32 Million |
+3.15% |
| 2021-12-31 | Skr165.00 Million ≈ $17.76 Million |
+207.31% |
| 2020-12-31 | Skr53.69 Million ≈ $5.78 Million |
+51.51% |
| 2019-12-31 | Skr35.44 Million ≈ $3.81 Million |
+27.02% |
| 2018-12-31 | Skr27.90 Million ≈ $3.00 Million |
-15.88% |
| 2017-12-31 | Skr33.16 Million ≈ $3.57 Million |
+61.08% |
| 2016-12-31 | Skr20.59 Million ≈ $2.22 Million |
+164.18% |
| 2015-12-31 | Skr7.79 Million ≈ $838.69K |
+201.32% |
| 2014-12-31 | Skr2.59 Million ≈ $278.34K |
-- |
About Nanexa AB
Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that ha… Read more